Solubilization of Poorly Soluble Drugs: Cyclodextrin-Based Formulations

Computational Pharmaceutics: Application of Molecular Modeling in Drug Delivery

Volumn , Issue , 2015, Pages 31-51

  Thakur, Sachin S ^a   Parekh, Harendra S ^a   Schwable, Carl H ^b   Gan, Yong ^c   Ouyang, Defang ^d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ASTON UNIVERSITY   (United Kingdom)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^d University of Macau   (Macao)

Author keywords

[No Author keywords available]

Indexed keywords

POORLY SOLUBLE DRUGS; ANALYTICAL METHOD; CD COMPLEX; CLINICAL OUTCOME; DIFFERENTIAL THERMAL ANALYSES (DTA); LIPOPHILIC PROPERTIES; PHARMACEUTICAL FORMULATION; PROCESSING PARAMETERS;

DRUG DELIVERY;

CALORIMETERS; CYCLODEXTRINS; DIFFERENTIAL SCANNING CALORIMETRY; DIFFERENTIAL THERMAL ANALYSIS; DRYING; HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY; QUANTUM THEORY; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY;

EID: 84987699693     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118573983.ch3     Document Type: Chapter

References (146)

1. Villiers, A., Sur la fermentation de la fecule par l'action du ferment butyrique. Comptes Rendus de l'Academie des Sciences, 1891. 112: 536-538.
2. Freudenberg, K., H. Boppel, and M. Meyer-Delius, Beobachtungen an der Starke. Naturwissenschaften, 1938. 26(8): 123-124.
3. French, D., The schardinger dextrins. Advances in Carbohydrate Chemistry, 1957. 12: 189-260.
4. Szejtli, J., Introduction and general overview of cyclodextrin chemistry. Chemical Reviews, 1998. 98(5): 1743-1753.
5. Pringsheim, H., A Comprehensive Survey of Starch Chemistry. 1928: Chemical Catalogue Co.: New York.
6. Freudenberg, K., Cramer, F., and Plieninger, H. Inclusion compounds of physiologically active organic compounds. 1953 Patent DE 895769 C.
7. Loftsson, T. and M.E. Brewster, Pharmaceutical applications of cyclodextrins: basic science and product development. Journal of Pharmacy and Pharmacology, 2010. 62(11): 1607-1621.
8. Cook, W.G., Cyclodextrins, in Handbook of Pharmaceutical Excipients, R.C. Rowe, Sheskey, PJ; Cook, W.G, Fenton, M.E., eds, 2013, Medicines Complete: New York.
9. Sabadini, E., T. Cosgrove, and F.C. Egidio, Solubility of cyclomaltooligosaccharides (cyclodextrins) in H2O and D2O: a comparative study. Carbohydrate Research, 2006. 341(2): 270.
10. Loftsson, T. and M.E. Brewster, Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. Journal of Pharmaceutical Sciences, 1996. 85(10): 1017-1025.
11. Kurkov, S.V. and T. Loftsson, Cyclodextrins. International Journal of Pharmaceutics, 2012, 436, 359-378.
12. Loftsson, T., Magnusdottir A., Masson M., Sigurjonsdottir J.F., Self-association and cyclodextrin solubilization of drugs. Journal of Pharmaceutical Sciences, 2002. 91(11): 2307-2316.
13. Loftsson, T., M. Masson, and M.E. Brewster, Self-association of cyclodextrins and cyclodextrin complexes. Journal of Pharmaceutical Sciences, 2004. 93(5): 1091-1099.
14. Messner, M., Kurkov, S.V., Jansook, P., Loftsson, T., Self-assembled cyclodextrin aggregates and nanoparticles. International Journal of Pharmaceutics, 2010. 387(1/2): 199.
15. Messner, M., Kurkov, S.V., Flavia-Piera, R., Brewster, M.E., et al., Self-assembly of cyclodextrins: the effect of the guest molecule. International Journal of Pharmaceutics, 2011. 408(1): 235-247.
16. Bonini, M., Rossi S., Karlsson G., Almgren M., et al., Self-assembly of P-cyclodextrin in water. Part 1: Cryo-TEM and dynamic and static light scattering. Langmuir, 2006. 22(4): 1478-1484.
17. Loftsson, T. and M.E. Brewster, Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes. Journal of Pharmacy and Pharmacology, 2011. 63(9): 1119-1135.
18. Loftsson, T. and A.M. Sigurdardottir, Improved acitretin delivery through hairless mouse skin by cyclodextrin complexation. International Journal of Pharmaceutics, 1995. 115(2): 255-258.
19. Zi, P., Yang X.H., Kuang H.F., Yang Y.S., et al., Effect of HPPCD on solubility and transdermal delivery of capsaicin through rat skin. International Journal of Pharmaceutics, 2008. 358(1): 151-158.
20. Loftsson, T., Frioriksdottir H., Ingvarsdottir G., Jonsdottir B., et al., The influence of 2- hydroxypropyl-P-cyclodextrin on diffusion rates and transdermal delivery of hydrocortisone. Drug Development and Industrial Pharmacy, 1994. 20(9): 1699-1708.
21. Doliwa, A., S. Santoyo, and P. Ygartua, Influence of piroxicam: hydroxypropyl-beta- cyclodextrin complexation on the in vitro permeation and skin retention of piroxicam. Skin Pharmacology and Physiology, 2001. 14(2): 97-107.
22. Jarvinen, K., Jarvinen T., Thompson D.O., Stella V.J., et al., The effect of a modified P- cyclodextrin, SBE4-P-CD, on the aqueous stability and ocular absorption of pilocarpine. Current Eye Research, 1994. 13(12): 897-905.
23. Loftsson, T., Gudmundsdottir H., Sigurjonsdottir J.F., et al., Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. International Journal of Pharmaceutics, 2001. 212(1): 29-40.
24. Kalaiselvan, R., Mohanta G.P., Madhusudan S., Manna P.K., et al., Enhancement of bioavailability and anthelmintic efficacy of albendazole by solid dispersion and cyclodextrin complexation techniques. Die Pharmazie - An International Journal of Pharmaceutical Sciences, 2007. 62(8): 604-607.
25. Le Corre, P., Dollo G., Chevanne F., Leverge R, Influence of hydroxypropyl-beta-cyclodextrin and dimethyl-beta-cyclodextrin on diphenhydramine intestinal absorption in a rat in situ model. International Journal of Pharmaceutics, 1998. 169(2): 221-228.
26. Arima, H., K. Motoyama, and T. Irie, Recent findings on safety profiles of cyclodextrins, cyclodextrin conjugates, and polypseudorotaxanes. Cyclodextrins in Pharmaceutics, Cosmetics, and Biomedicine: Current and Future Industrial Applications, 2011:Wiley-Blackwell: New York, pp. 91-122.
27. Loftsson, T. and M.E. Brewster, Cyclodextrins as functional excipients: methods to enhance complexation efficiency. Journal of Pharmaceutical Sciences, 2012, 101(9):3019-3032.
28. Peeters, P., Passier, P., Smeets, J., Zwiers, A., et al., Sugammadex is cleared rapidly and primarily unchanged via renal excretion. Biopharmaceutics and Drug Disposition, 2011. 32(3): 159-167.
29. Stella, V.J. and Q. He, Cyclodextrins. Toxicologic Pathology, 2008. 36(1): 30-42.
30. Loftsson, T., P. Jarho, M. Masson, and T. Jarvinen, Cyclodextrins in drug delivery. Expert Opinion on Drug Delivery, 2005. 2(2): 335-351.
31. USFDA, GRAS Notice 000155: alpha-Cyclodextrin. 2004.
32. USFDA, GRAS Notice 000074: beta-Cyclodextrin. 2001.
33. USFDA, GRAS Notice 000046: gamma-Cyclodextrin. 2000.
34. Muraoka, A., T. Tokumura, and Y. Machida, Evaluation of the bioavailability of flurbiprofen and its P-cyclodextrin inclusion complex in four different doses upon oral administration to rats. European Journal of Pharmaceutics and Biopharmaceutics, 2004. 58(3): 667-671.
35. Chow, D.D. and A.H. Karara, Characterization, dissolution and bioavailability in rats of ibuprofen-P-cyclodextrin complex system. International Journal of Pharmaceutics, 1986. 28(2): 95-101.
36. Hostetler, J.S., L. Hanson, and D. Stevens, Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrobial Agents and Chemotherapy, 1992. 36(2): 477-480.
37. Luengo, J., Aranguiz T., Sepulveda J., et al., Preliminary pharmacokinetic study of different preparations of acyclovir with P-cyclodextrin. Journal of Pharmaceutical Sciences, 2002. 91(12): 2593-2598.
38. McEwen, J., Clinical pharmacology of piroxicam-beta-cyclodextrin: implications for innovative patient care. Clinical Drug Investigation, 2000. 19(S2): 27-31.
39. Jambhekar, S., R. Casella, and T. Maher, The physicochemical characteristics and bioavailability of indomethacin from P-cyclodextrin, hydroxyethyl-P-cyclodextrin, and hydroxypropyl-P-cyclodextrin complexes. International Journal of Pharmaceutics, 2004. 270(1): 149-166.
40. Haeberlin, B., T. Gengenbacher, A. Meinzer, et al., Cyclodextrins-useful excipients for oral peptide administration? International Journal of Pharmaceutics, 1996. 137(1): 103-110.
41. Uekama, K., Fujinaga T., Hirayama F., et al., Improvement of the oral bioavailability of digitalis glycosides by cyclodextrin complexation. Journal of Pharmaceutical Sciences, 1983. 72(11): 1338-1341.
42. Pathak, S.M., P. Musmade, S. Dengle, et al., Enhanced oral absorption of saquinavir with Methyl-Beta-Cyclodextrin-preparation and in vitro and in vivo evaluation. European Journal of Pharmaceutical Sciences, 2010. 41(3): 440-451.
43. Agueros, M., V. Zabaleta, S. Espuelas, et al., Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly (anhydride) nanoparticles. Journal of Controlled Release, 2010. 145(1): 2-8.
44. Loftsson, T., Effects of cyclodextrins on the chemical stability of drugs in aqueous solutions. Drug Stability, 1995. 1: 22-33.
45. Garcia-Fuentes, M., A. Trapani, and M. Alonso, Protection of the peptide glutathione by complex formation with a-cyclodextrin: NMR spectroscopic analysis and stability study. European Journal of Pharmaceutics and Biopharmaceutics, 2006. 64(2): 146-153.
46. Loftsson, T., J. Baldvinsdottir, and A.M. Sigurdardottir, The effect of cyclodextrins on the solubility and stability of medroxyprogesterone acetate and megestrol acetate in aqueous solution. International Journal of Pharmaceutics, 1993. 98(1): 225-230.
47. Gorecka, B.A., Y.D. Sanzgiri, A.M. Sigurdardottir, et al., Effect of SBE4-beta-CD, a sulfobutyl ether beta-cyclodextrin, on the stability and solubility of O6-benzylguanine (NSC-637037) in aqueous solutions. International Journal of Pharmaceutics, 1995. 125(1): 55-61.
48. Uekama, K., T. Fujinaga, F. Hirayama, et al., Effects of cyclodextrins on the acid hydrolysis of digoxin. Journal of Pharmacy and Pharmacology, 1982. 34(10): 627-630.
49. Loftsson, T., M.E. Brewster, and M. Masson, Role of cyclodextrins in improving oral drug delivery. American Journal of Drug Delivery, 2004. 2(4): 261-275.
50. Santucci, L., Fiorucci S, Chiucchiu S, et al., Placebo-controlled comparison of piroxicam-P- cyclodextrin, piroxicam, and indomethacin on gastric potential difference and mucosal injury in humans. Digestive Diseases and Sciences, 1992. 37(12): 1825-1832.
51. Espinar, F., S. Anguiano Igea, J. Blanco Mendez, et al., Reduction in the ulcerogenicity of naproxen by complexation with P-cyclodextrin. International Journal of Pharmaceutics, 1991. 70(1): 35-41.
52. Govindarajan, R. and M.S. Nagarsenker, Formulation studies and in vivo evaluation of a flurbiprofen-hydroxypropyl P-cyclodextrin system. Pharmaceutical Development and Technology, 2005. 10(1): 105-114.
53. Szejtli, J. and L. Szente, Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins. European Journal of Pharmaceutics and Biopharmaceutics, 2005. 61(3): 115-125.
54. Lantz, A.W., M.A. Rodriguez, S.M. Wetterer, and D.W. Armstrong, Estimation of association constants between oral malodor components and various native and derivatized cyclodextrins. Analytica Chimica Acta, 2006. 557(1): 184-190.
55. Fridriksdottir, H., Loftsson T., Gudmundsson J.A., et al., Design and in vivo testing of 17 beta- estradiol-HP beta CD sublingual tablets. Pharmazie, 1996. 51(1): 39-42.
56. Stuenkel, C., R. Dudley, and S. Yen, Sublingual administration of testosterone-hydroxypropyl-P- cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 1991. 72(5): 1054-1059.
57. CycloLab, Approved Pharmaceutical Products Containing Cyclodextrins. 2013.
58. Merkus, F.W., J.C. Verhoef, E. Marttin, et al., Cyclodextrins in nasal drug delivery. Advanced Drug Delivery Reviews, 1999. 36(1): 41-57.
59. Kondo, T., K. Nishimura, T. Irie, K. Uekama, Cyclodextrin derivatives that modify nasal absorption of morphine and its entry into cerebrospinal fluid in the rat. Pharmacy and Pharmacology Communications, 1995. 1(4): 163-166.
60. Hermens, W.A., Deurloo, M.J.M., Romeyn S.G., et al., Nasal absorption enhancement of 17P- estradiol by dimethyl-P-cyclodextrin in rabbits and rats. Pharmaceutical Research, 1990. 7(5): 500-503.
61. Laza-Knoerr, A., R. Gref, and P. Couvreur, Cyclodextrins for drug delivery. Journal of Drug Targeting, 2010. 18(9): 645-656.
62. Asai, K., M. Morishita, H. Hosoda, et al., The effects of water-soluble cyclodextrins on the histological integrity of the rat nasal mucosa. International Journal of Pharmaceutics, 2002. 246(1): 25-35.
63. Ghate, D. and H.F. Edelhauser, Ocular drug delivery. Expert Opinion on Drug Delivery, 2006. 3(2): 275-287.
64. Loftsson, T. and T. Jarvinen, Cyclodextrins in ophthalmic drug delivery. Advanced Drug Delivery Reviews, 1999. 36(1): 59-79.
65. Loftsson, T., Frioriksdottir H., Stefansson E., et al., Topically effective ocular hypotensive acet- azolamide and ethoxyzolamide formulations in rabbits. Journal of Pharmacy and Pharmacology, 1994. 46(6): 503-504.
66. Suhonen, P., T. Jarvinen, K. Lehmussaari, et al., Ocular absorption and irritation of pilocarpine prodrug is modified with buffer, polymer, and cyclodextrin in the eyedrop. Pharmaceutical Research, 1995. 12(4): 529-533.
67. Matsuda, H. and H. Arima, Cyclodextrins in transdermal and rectal delivery. Advanced Drug Delivery Reviews, 1999. 36(1): 81-99.
68. Felton, L.A., C.J. Wiley, and D.A. Godwin, Influence of hydroxypropyl-P-cyclodextrin on the transdermal permeation and skin accumulation of oxybenzone. Drug Development and Industrial Pharmacy, 2002. 28(9): 1117-1124.
69. Irie, T. and K. Uekama, Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. Journal of Pharmaceutical Sciences, 1997. 86(2): 147-162.
70. Ohtani,Y., Irie T., Uekama K., et al., Differential effects of alpha-, beta- and gamma-cyclodextrins on human erythrocytes. European Journal of Biochemistry/FEBS, 1989. 186(1/2): 17.
71. Aagaard, L. and J.J. Rossi, RNAi therapeutics: principles, prospects and challenges. Advanced Drug Delivery Reviews, 2007. 59(2): 75-86.
72. Li, W. and F.C. Szoka, Lipid-based nanoparticles for nucleic acid delivery. Pharmaceutical Research, 2007. 24(3): 438-449.
73. Chaturvedi, K., Ganguly K., Kulkarni AR, et al., Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review. Expert Opinion on Drug Delivery, 2011. 8(11): 1455-1468.
74. Davis, M.E., The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Molecular Pharmaceutics, 2009. 6(3): 659-668.
75. ClinicalTrials.gov, Safety Study of CALAA-01 to Treat Solid Tumor Cancers, 2008. http:// www.clinicaltrials.gov/ct2/show/NCT00689065 (accessed 14 May 2013).
76. Vyas, A., S. Saraf, and S. Saraf, Cyclodextrin based novel drug delivery systems. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2008. 62(1): 23-42.
77. ISP Pharmaceuticals, CAVAMAX Cyclodextrins: Forming and Analyzing Drug Inclusion Complexes, I.S. Products Editor, 2006.
78. Del Valle, E.M., Cyclodextrins and their uses: a review. Process Biochemistry, 2004. 39(9): 1033-1046.
79. Jun, S.W., M.S. Kim, J.S. Kim, et al., Preparation and characterization of simvastatin/ hydroxypropyl-P-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. European Journal of Pharmaceutics and Biopharmaceutics, 2007. 66(3): 413-421.
80. Wulff, M. and M. Alden, Solid state studies of drug-cyclodextrin inclusion complexes in PEG 6000 prepared by a new method. European Journal of Pharmaceutical Sciences, 1999. 8(4): 269-281.
81. Toropainen, T., S. Velaga, T. Heikkila, et al., Preparation of budesonide/y-cyclodextrin complexes in supercritical fluids with a novel SEDS method. Journal of Pharmaceutical Sciences, 2006. 95(10): 2235-2245.
82. Wen, X., F. Tan, Z. Jing, and Z. Liu, Preparation and study the 1: 2 inclusion complex of carvedilol with P-cyclodextrin. Journal of Pharmaceutical and Biomedical Analysis, 2004. 34(3): 517-523.
83. Davis, M.E. and M.E. Brewster, Cyclodextrin-based pharmaceutics: past, present and future. Nature Reviews Drug Discovery, 2004. 3(12): 1023-1035.
84. Atwood, J.L. and J.-M. Lehn, Comprehensive Supramolecular Chemistry: Supramolecular Reactivity and Transport: Bioinorganic Systems. Vol. 5. 1996: Elsevier.
85. Kurkov, S.V., E.V. Ukhatskaya, and T. Loftsson, Drug/cyclodextrin: beyond inclusion complex- ation. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2011. 69(3/4): 297-301.
86. Loftsson, T., K. Matthiasson, and M. Masson, The effects of organic salts on the cyclodextrin solubilization of drugs. International Journal of Pharmaceutics, 2003. 262(1): 101-107.
87. Liu, L. and Q.-X. Guo, The driving forces in the inclusion complexation of cyclodextrins. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2002. 42(1): 1-14.
88. Szente, L., J. Szejtli, and G.L. Kis, Spontaneous opalescence of aqueous y-Cyclodextrin solutions: Complex formation or self-aggregation? Journal of Pharmaceutical Sciences, 1998. 87(6): 778-781.
89. Puskas, I., M. Schrott, M. Malanga, L. Szente, Characterization and control of the aggregation behavior of cyclodextrins. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2012: 1-8.
90. Auzely-Velty, R., F. Djedaini-Pilard, S. Desert, et al., Micellization of hydrophobically modified cyclodextrins. 1. Micellar structure. Langmuir, 2000. 16(8): 3727-3734.
91. Witte, F. and H. Hoffmann, Aggregation behavior of hydrophobically modified P-cyclodextrins in aqueous solution. Journal of Inclusion Phenomena and Molecular Recognition in Chemistry, 1996. 25(1/3): 25-28.
92. Loftsson, T., M. Masson, and H.H. Sigurdsson, Cyclodextrins and drug permeability through semi-permeable cellophane membranes. International Journal of Pharmaceutics, 2002. 232(1): 35-43.
93. de Jesus, M.B., Fraceto, L.F., Florencia Martini, M., et al., Non-inclusion complexes between riboflavin and cyclodextrins. Journal of Pharmacy and Pharmacology, 2012. 64(6): 832-842.
94. Jansook, P., G.C. Ritthidej, H. Ueda, et al., yCD/HPyCD mixtures as solubilizer: solid-state characterization and sample dexamethasone eye drop suspension. Journal of Pharmacy and Pharmaceutical Sciences, 2010. 13(3): 336-350.
95. Ribeiro, R.R., Ferreria, W.A., Martins, P.S., et al., Prolonged absorption of antimony (V) by the oral route from non-inclusion meglumine antimoniate-P-cyclodextrin conjugates. Biopharmaceutics and Drug Disposition, 2010. 31(2/3): 109-119.
96. Singh, R., N. Bharti, J. Madan, S.N. Hiremath, Characterization of cyclodextrin inclusion complexes-a review. Journal of Pharmaceutical Science and Technology, 2010. 2(3): 171- 183.
97. Marques, H., J. Hadgraft, and I. Kellaway, Studies of cyclodextrin inclusion complexes. I. The salbutamol-cyclodextrin complex as studied by phase solubility and DSC. International Journal of Pharmaceutics, 1990. 63(3): 259-266.
98. Hassan, M.A., M.S. Suleiman, and N.M. Najib, Improvement of the in vitro dissolution characteristics of famotidine by inclusion in P-cyclodextrin. International Journal of Pharmaceutics, 1990. 58(1): 19-24.
99. Dqbrowska, M., J. Krzek, and E. Minkina, Stability analysis of cefaclor and its inclusion complexes of P-cyclodextrin by thin-layer chromatography and densitometry. Journal of Planar Chromatography - Modern TLC, 2012. 25(2): 127-132.
100. Morin, N., Cornet, S., Guinchard, C., et al., HPLC retention and inclusion of imidazole derivatives using hydroxypropyl-P-cyclodextrin as a mobile phase additive, Journal of Liquid Chromatography and Related Technologies, 2000. 23: 727-739.
101. Flood, K.G., E.R. Reynolds, and N.H. Snow, Characterization of inclusion complexes of betamethasone-related steroids with cyclodextrins using high-performance liquid chromatography. Journal of Chromatography A, 2000. 903(1): 49-65.
102. Jadhav, G. and P. Vavia, Physicochemical, in silico and in vivo evaluation of a danazol-P- cyclodextrin complex. International Journal of Pharmaceutics, 2008. 352(1): 5-16.
103. Estrada, E., I. Perdomo-Lopez, and J.J. Torres-Labandeira, Molecular modeling (MM2 and PM3) and experimental (NMR and thermal analysis) studies on the inclusion complex of salbutamol and P-cyclodextrin. The Journal of Organic Chemistry, 2000. 65(25): 8510-8517.
104. Fronza, G., A. Mele, E. Redenti, P. Ventura, 1H NMR and molecular modeling study on the inclusion complex P-cyclodextrin-indomethacin. The Journal of Organic Chemistry, 1996. 61(3): 909-914.
105. Schneider, H.-J., Hacket F., Rudiger V., et al., NMR studies of cyclodextrins and cyclodextrin complexes. Chemical Reviews, 1998. 98(5): 1755-1786.
106. Redenti, E., Zanol M., Ventura P., et al., Raman and solid state 13C-NMR investigation of the structure of the 1: 1 amorphous piroxicam: P-cyclodextrin inclusion compound. Biospectroscopy, 1999. 5(4): 243-251.
107. Hasegawa, Y., Inoue Y., Deguchi K., et al., Molecular dynamics of a polyaniline/P-cyclodex- trin complex investigated by 13C solid-state NMR. The Journal of Physical Chemistry B, 2012. 116(6): 1758-1764.
108. Van Hees, T., Geraldine, P., Brigitte E., et al., Application of supercritical carbon dioxide for the preparation of a piroxicam-P-cyclodextrin inclusion compound. Pharmaceutical Research, 1999. 16(12): 1864-1870.
109. Lin, S.-Z., D. Wouessidjewe, M.C. Poelman, et al., Indomethacin and cyclodextrin complexes. International Journal of Pharmaceutics, 1991. 69(3): 211-219.
110. Blanco, J., J.L. Vila-Jato, F. Otero, S. Anguiano, Influence of method of preparation on inclusion complexes of naproxen with different cyclodextrins. Drug Development and Industrial Pharmacy, 1991. 17(7): 943-957.
111. Bilensoy, E., M. Abdur Rouf, I., Vural, et al., Mucoadhesive, thermosensitive, prolonged- release vaginal gel for clotrimazole: P-cyclodextrin complex. AAPS PharmSciTech, 2006. 7(2): E54-E60.
112. de Oliveira, V.E., Almeida E.W.C., Castro H.V., et al., Carotenoids and P-cyclodextrin inclusion complexes: Raman spectroscopy and theoretical investigation. The Journal of Physical Chemistry A, 2011. 115(30): 8511-8519.
113. Rossi, B., P. Verrochio, G. Viliani, et al., Vibrational properties of ibuprofen-cyclodextrin inclusion complexes investigated by Raman scattering and numerical simulation. Journal of Raman Spectroscopy, 2009. 40(4): 453-458.
114. Sinha, V., Anitha R., Ghosh S., et al., Complexation of celecoxib with P-cyclodextrin: Characterization of the interaction in solution and in solid state. Journal of Pharmaceutical Sciences, 2005. 94(3): 676-687.
115. Lee, P.S., Han J.Y., Song T.W., et al., Physicochemical characteristics and bioavailability of a novel intestinal metabolite of ginseng saponin (IH901) complexed with P-cyclodextrin. International Journal of Pharmaceutics, 2006. 316(1): 29-36.
116. Pralhad, T. and K. Rajendrakumar, Study of freeze-dried quercetin-cyclodextrin binary systems by DSC, FT-IR, X-ray diffraction and SEM analysis. Journal of Pharmaceutical and Biomedical Analysis, 2004. 34(2): 333-339.
117. Zingone, G. and F. Rubessa, Preformulation study of the inclusion complex warfarin-P-cyclo- dextrin. International Journal of Pharmaceutics, 2005. 291(1): 3-10.
118. Park, J.S., S. Jeong, B. Ahn, et al., Selective response of cyclodextrin-dye hydrogel to metal ions. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2011. 71(1/2): 79-86.
119. Carlstedt, J., A. Bilalov, E. Krivtsova, et al., Cyclodextrin-surfactant coassembly depends on the cyclodextrin ability to crystallize. Langmuir, 2012. 28(5): 2387-2394.
120. Tu, C.-W., S.-W. Kuo, and F.-C. Chang, Supramolecular self-assembly through inclusion complex formation between poly (ethylene oxide-bN-isopropylacrylamide) block copolymer and a-cyclodextrin. Polymer, 2009. 50(13): 2958-2966.
121. Polarz, S., Smarsly, B., Bronstein, L., et al., From cyclodextrin assemblies to porous materials by silica templating. Angewandte Chemie International Edition, 2001. 40(23): 4417-4421.
122. Villari, V., Mazzaglia A., Darcy R., et al., Nanostructures of cationic amphiphilic cyclodextrin complexes with DNA. Biomacromolecules, 2013. 14(3): 811-817.
123. Bekers, O., T. Loftsson, Matthias, K., et al., Cyclodextrins in the pharmaceutical field. Drug Development and Industrial Pharmacy, 1991. 17(11): 1503-1549.
124. Aicart, E. and E. Junquera, Complex formation between purine derivatives and cyclodextrins: a fluorescence spectroscopy study. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2003. 47(3-4): 161-165.
125. Wei, Y.-L., Ding, L.H., Dong, C., et al., Study on inclusion complex of cyclodextrin with methyl xanthine derivatives by fluorimetry. Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy, 2003. 59(12): 2697-2703.
126. Masson, M., T. Loftsson, S. Jonsdottir, et al., Stabilisation of ionic drugs through complexation with non-ionic and ionic cyclodextrins. International Journal of Pharmaceutics, 1998. 164(1): 45-55.
127. Masson, M., Sigurdardottir, B.V., Matthiasson, K., et al., Investigation of drug-cyclodextrin complexes by a phase-distribution method: some theoretical and practical considerations. Chemical and Pharmaceutical Bulletin, 2005. 53(8): 958-964.
128. Ugwu, S.O., Alcala M.J., Bhardwaj R., Blanchard J., The application of equilibrium dialysis to the determination of drug-cyclodextrin stability constants. Journal of Inclusion Phenomena and Molecular Recognition in Chemistry, 1996. 25(1/3): 173-176.
129. Cai, W.S., Wang, T., Zhe Liu, Y., et al., Free energy calculations for cyclodextrin inclusion complexes. Current Organic Chemistry, 2011. 15(6): 839-847.
130. Djemil, R. and D. Khatmi, Quantum mechanical study of complexation of dopamine and epinephrine with P-Cyclodextrin using PM6, ONIOM and NBO analysis. Journal of Computational and Theoretical Nanoscience, 2012. 9(10): 1571-1576.
131. Anconi, C.P.A., da Silva Delgado, L., Alves Dos Reis, J.B., et al., Inclusion complexes of a- cyclodextrin and the cisplatin analogues oxaliplatin, carboplatin and nedaplatin: a theoretical approach. Chemical Physics Letters, 2011. 515(1/3): 127-131.
132. Ramlrez-Galicia, G., R. Garduno-Juarez, and M.G. Vargas, Effect of water molecules on the fluorescence enhancement of Aflatoxin B1 mediated by Aflatoxin B1:P-cyclodextrin complexes. A theoretical study. Photochemical and Photobiological Sciences, 2007. 6(1): 110-118.
133. Wickstrom, L., He, P., Gallicchio, E., and Levy, R.M., Large scale affinity calculations of cyclodextrin host-guest complexes: Understanding the role of reorganization in the molecular recognition process. Journal of Chemical Theory and Computation, 2013. 9(7): 3136-3150.
134. He, J., Chipot, C., Shao, X., et al., Cyclodextrin-mediated recruitment and delivery of amphotericin B. Journal of Physical Chemistry C, 2013. 117(22): 11750-11756.
135. Jiao, A., Zhou, X., Xu, X., and Jin, Z., Molecular dynamics simulations of cyclodextrin- cumene hydroperoxide complexes in water. Computational and Theoretical Chemistry, 2013. 1013: 1-6.
136. El-Barghouthi, M.I., C. Jaime, N.A. Al-Sakhen, et al., Molecular dynamics simulations and MM-PBSA calculations of the cyclodextrin inclusion complexes with 1-alkanols, para-substituted phenols and substituted imidazoles. Journal of Molecular Structure: THEOCHEM, 2008. 853(1/3): 45-52.
137. Mota, G.V.S., C.X. Oliveira, A.M.J.C. Neto, et al., Inclusion complexation of praziquantel and P-cyclodextrin, combined molecular mechanic and monte carlo simulation. Journal of Computational and Theoretical Nanoscience, 2012. 9(8): 1090-1095.
138. Pereira, C.C.L., Nolasco, M., Braga, S.S., et al., A combined theoretical-experimental study of the inclusion of niobocene dichloride in native and permethylated P-cyclodextrins. Organometallics, 2007. 26(17): 4220-4228.
139. Georg, H.C., K. Coutinho, and S. Canuto, A look inside the cavity of hydrated a-cyclodextrin: a computer simulation study. Chemical Physics Letters, 2005. 413(1/3): 16-21.
140. Liu, B., Li, W., Zhao, J., et al., Physicochemical characterisation of the supramolecular structure of luteolin/cyclodextrin inclusion complex. Food Chemistry, 2013. 141(2): 900-906.
141. Miletic, T., Kyriakos, K., Graovac, A., and Ibric, S., Spray-dried voriconazole-cyclodextrin complexes: solubility, dissolution rate and chemical stability. Carbohydrate Polymers, 2013. 98(1): 122-131.
142. Paramasivaganesh, K., Srinivasan, K., Manivel, A. et al., Studies on inclusion complexation between 4,4'-dihydroxybiphenyl and P-cyclodextrin by experimental and theoretical approach. Journal of Molecular Structure, 2013. 1048: 399-409.
143. Ghasemi, J.B., M. Salahinejad, M.K. Rofouei, M.H. Mousazadeh, Docking and 3D-QSAR study of stability constants of benzene derivatives as environmental pollutants with a- cyclodextrin. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2012. 73(1/4): 405-413.
144. Perez-Garrido, A., Morales Helguera, A., Corderio, M.N.D.S., and Escudero, GA., QSPR modelling with the topological substructural molecular design approach: P-cyclodextrin com- plexation. Journal of Pharmaceutical Sciences, 2009. 98(12): 4557-4576.
145. Perez-Garrido, A., H.A. Morales, G.A. Abellan, et al., Convenient QSAR model for predicting the complexation of structurally diverse compounds with P-cyclodextrins. Bioorganic and Medicinal Chemistry, 2009. 17(2): 896-904.
146. Wang, W., Donini, O., Reyes, C.M., and Kollman, P.A., Biomolecular simulations: recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein- protein, and protein-nucleic acid noncovalent interactions. Annual Review of Biophysics and Biomolecular Structure, 2001. 30: 211-243.